KLOW 80mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

KLOW is a single 80 mg vial holding four research peptides blended together in one fixed ratio: GHK-Cu 50 mg, BPC-157 10 mg, KPV 10 mg and TB-500 10 mg[1][5]. Because all four share one vial, they are reconstituted and dosed together — the components cannot be adjusted independently. This educational page outlines a once-daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. Every component is an unapproved research chemical, not a medicine, and the four-peptide combination has not been validated by any human trial — presented for research and educational use only.

Add 3.0 mL bacteriostatic water to the one 80 mg vial → ~26.67 mg/mL total blend. At this dilution 1 unit ≈ 267 mcg of combined peptide.
2,667–5,333 mcg of total blend once daily, titrated upward gradually across an 8–12 week course (about 10–20 units).
At ~26.67 mg/mL, 10 units ≈ 2,667 mcg, 15 units ≈ 4,000 mcg and 20 units ≈ 5,333 mcg on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

One combined 80 mg vial, dosed by total blend — step by step

Standard / Gradual Approach (3 mL = ~26.67 mg/mL)

Phase / Week(s)	Total Blend Dose (1× daily)	Volume (U-100 units / mL)
Weeks 1–2	2,667 mcg total	~10 units (0.10 mL)
Weeks 3–6	4,000 mcg total	~15 units (0.15 mL)
Weeks 7–12	5,333 mcg total	~20 units (0.20 mL)

All four peptides sit in the same 80 mg vial, so every unit drawn delivers the fixed blend ratio: 62.5% GHK-Cu and 12.5% each of BPC-157, KPV and TB-500. The figures below are total-blend micrograms; the per-component amounts follow automatically and cannot be tuned on their own.
Reconstitute: Add 3.0 mL bacteriostatic water to the one 80 mg vial → final concentration ~26.67 mg/mL of total blend, where 1 unit ≈ 267 mcg.
Convert: units = total mcg ÷ 267. Once-daily subcutaneous injection for 8–12 weeks, optionally extended to ~16 weeks.
Per-component breakdown (fixed ratio). At the 10-unit starting dose, 2,667 mcg of total blend works out to roughly 1,667 mcg GHK-Cu plus ~333 mcg each of BPC-157, KPV and TB-500. The same 62.5 / 12.5 / 12.5 / 12.5 split scales up at 15 and 20 units.
Frequency: one subcutaneous injection each day, titrating up as tolerated. These figures come from how the fixed-ratio blend reconstitutes, not from any approved human dosing of the combination[3][4].

Reconstitution Steps

Draw 3.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until the blend is fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Because all four peptides share one vial, you reconstitute and dose the blend as a single solution; the ratio between components is fixed and cannot be changed. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptides.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume an 8–16 week course of once-daily injections with gradual titration. One 80 mg KLOW vial reconstituted to 3.0 mL covers roughly 15–30 daily doses depending on the phase.

One vial reconstituted to 3.0 mL lasts about 15–30 days; plan extra to cover the full cycle.
8 weeks: ~2–3 vials
12 weeks: ~3–4 vials
16 weeks: ~4–5 vials
Per injection: 1 syringe
8 weeks (once daily): ~56 syringes
16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 80 mg vial for reconstitution.
8 weeks (~3 vials): ~9 mL → 1 bottle
16 weeks (~5 vials): ~15 mL → 2 bottles
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs
8 weeks (once daily): ~112 swabs → 1–2 boxes

Protocol Overview

A concise summary of the once-daily regimen for the combined four-peptide vial.

▪Goal: Explore the soft-tissue and anti-inflammatory pathways of four research peptides delivered together — each effect is reported preclinically for the individual components, and the combination itself is not validated in humans[5][6].
▪Schedule: Daily subcutaneous injections for 8–12 weeks, optionally extended to ~16 weeks.
▪Dose Range: 2,667–5,333 mcg of total blend per day (~10–20 units) with gradual titration.
▪Reconstitution: 3.0 mL bacteriostatic water per 80 mg vial gives ~26.67 mg/mL; 1 unit ≈ 267 mcg total.
▪Fixed ratio: 62.5% GHK-Cu / 12.5% each BPC-157, KPV and TB-500 — components share one vial and are not independently adjustable.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

A suggested daily titration approach for the combined vial, expressed as total blend.

▪Start: Begin at 2,667 mcg total (~10 units) once daily to gauge tolerability.
▪Titrate: Step up to ~4,000 mcg (~15 units) around weeks 3–6 as tolerated.
▪Target: Reach about 5,333 mcg total (~20 units) daily by weeks 7–12.
▪Cycle Length: Typically 8–12 weeks; some research schedules extend to ~16 weeks.
▪Timing: Inject at a consistent time each day and rotate injection sites systematically. All four peptides move together — you cannot raise one without raising the rest.

Storage Instructions

Correct storage is what preserves the blend’s stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep daily administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
▪Regulatory note: None of the four components is FDA-approved for human use, and because the blend contains BPC-157 and TB-500 it should be treated as WADA-prohibited for athletes[10].

How This Works

KLOW combines four research peptides, each with a separate, mostly preclinical proposed mechanism. They are blended in one vial, but they do not act on a single shared pathway — the idea of combined “synergy” is a hypothesis, not a demonstrated effect.

GHK-Cu is a copper-binding tripeptide (glycyl-L-histidyl-L-lysine) studied in cell and animal models for collagen synthesis, angiogenesis and skin remodelling[1].
BPC-157 is a synthetic fragment derived from a gastric protein, examined preclinically for soft-tissue and tendon repair and gut-protective effects[5].
KPV is the tripeptide Lys-Pro-Val, the C-terminal sequence of α-MSH, investigated in cell models for anti-inflammatory activity, partly via NF-κB signalling[6].
TB-500 is a synthetic fragment of Thymosin Beta-4 (the Ac-LKKTETQ region) linked in preclinical work to cell migration and angiogenesis through G-actin regulation[11][12].
Important caveat: every claim above comes from cell-culture or animal studies of the individual peptides. There are no completed human trials of this four-peptide blend, and the combination has not been shown to be safer or more effective than any component alone[13].
KLOW and its components are not approved medicines. They are unapproved research chemicals presented here for research and educational purposes only.

Lifestyle Factors

Habits that may support recovery alongside the protocol.

▪Nutrition: Keep protein intake adequate to give tissue repair the building blocks it needs.
▪Activity & rest: Pair appropriate movement with real recovery time and avoid overtraining during an injury-recovery phase.
▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
▪Stress: Manage stress with evidence-based practices, since it influences overall healing.

Potential Benefits & Side Effects

What preclinical literature describes for the individual peptides; human evidence for the blend is absent and individual results vary.

▪Tissue repair (preclinical): GHK-Cu, BPC-157 and TB-500 are individually reported to support wound healing, collagen and angiogenesis in animal and cell models[5][6].
▪Anti-inflammatory signalling (preclinical): KPV has shown anti-inflammatory activity via NF-κB in cell studies[11].
▪Convenience: A single vial and one daily injection cover all four peptides, simplifying handling.
▪Note on humans: These benefits are not established in humans, and no trial has tested the four-peptide combination[13].
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
▪Unknown combined profile: Human safety data is absent for the blend, so caution and monitoring are advised.
▪Sport restriction: The blend contains BPC-157 and TB-500, both WADA-prohibited — treat KLOW as banned for athletes.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[14][15].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for the KLOW (80 mg blend) vial.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. The product URL uses a legacy “klow-70mg” slug, but the vial and its component sum are 80 mg. Verify current product details on the supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for KLOW 80mg.

KLOW (80 mg Vial) Dosage Protocol Open source
1 GHK-Cu (PubMed) Copper tripeptide GHK-Cu and its roles in collagen synthesis, angiogenesis and skin remodelling. View Source ↗ Open source
2 Oligopeptides & Tissue Repair (PubMed) Review of copper-binding peptides in wound healing and regenerative signalling. View Source ↗ Open source
3 BPC-157 Reference Dosing Commonly cited preclinical research dosing ranges for BPC-157 soft-tissue studies. View Source ↗ Open source
4 Peptide Blend Handling General reconstitution and dosing practice for multi-peptide research vials. View Source ↗ Open source
5 BPC-157 (PubMed) Body protection compound BPC-157 in preclinical soft-tissue, tendon and gut-repair models. View Source ↗ Open source
6 KPV / α-MSH (PubMed) KPV tripeptide (Lys-Pro-Val), the C-terminal of α-MSH, and anti-inflammatory NF-κB signalling. View Source ↗ Open source
7 Peptide Storage Guide Best practices for storing lyophilized peptides (temperature, humidity and light protection). View Source ↗ Open source
8 Bacteriostatic Water Guidance Bacteriostatic water for injection: multi-dose vial stability and handling. View Source ↗ Open source
9 NCBI Bookshelf Best practices for subcutaneous injection: aseptic technique and site rotation. View Source ↗ Open source
10 WADA Prohibited List Classification of BPC-157 and TB-500 as prohibited substances in competitive sport. View Source ↗ Open source
11 KPV Anti-Inflammatory Activity (PubMed) KPV reduces inflammation in cell and colitis models via NF-κB pathway modulation. View Source ↗ Open source
12 Thymosin Beta-4 / TB-500 (PubMed) Thymosin beta-4 active fragment (TB-500): cell migration and angiogenesis via G-actin regulation. View Source ↗ Open source
13 ClinicalTrials.gov Trial registry search — no completed efficacy trials of the GHK-Cu / BPC-157 / KPV / TB-500 combination. View Source ↗ Open source
14 Centers for Disease Control and Prevention (CDC) Subcutaneous injection technique: angle, site and no-aspiration guidance. View Source ↗ Open source
15 Subcutaneous Injection Technique (Patient Education) How to administer a subcutaneous injection: clinical technique guidelines. View Source ↗ Open source
16 Prime Lab Peptides KLOW (80 mg blend) product page — purity specifications and certificates of analysis (legacy klow-70mg slug). View Source ↗ Open source

Contents